Lignin in Treatment of Helicobacter Pylori Infection

The goal of this clinical trial is to learn if drug hydrolyzed lignin works to treat H pylori infection in adults. It will also learn about the safety of drug lignin n the sitting of H pylori infection, and if it halts the side effects associated with H pylori triple therapy. The main questions it aims to answer are: * Does drug hydrolyzed lignin improve the H pylori eradiation rate when it is added to the standard triple therapy used in treatment of H pylori? * What medical problems do participants experience when taking drug hydrolyzed lignin? Researchers will compare drug hydrolyzed lignin to a placebo (a look-alike substance that contains no drug) to see if drug hydrolyzed lignin works to treat H pylori. Participants will: * Take drug hydrolyzed lignin or a placebo every day for 2 weeks beside the standard triple therapy * Visit the clinic once every 1 week for checkup and questionnaire filling * Check for H pylori eradication after treatment

NCT Number	NCT07246681
Lead Sponsor	Zagazig University Collaborators: EVERGREEN MEDICAL COMPANY, Kafrelsheikh University, Al-Azhar University, Ain Shams University, Egypt, Security Forces Hospital Riyadh, Saudi Arabia, Alyousif Hospital, Alkhobar, Saudi Arabia
Conditions	HELICOBACTER PYLORI INFECTIONS
Enrollment	70 participants
Start Date	2025-10-31
Primary Completion	2026-02-15 (estimated)
Study Completion	2026-03-15 (estimated)
Updated on ClinicalTrials.gov	2025-11-24